Barclays analyst Luke Sergott raised the firm’s price target on Iqvia (IQV) to $200 from $185 and keeps an Equal Weight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Early notable gainers among liquid option names on October 1st
- Private Markets: Dyna Robotics raises $120M from Nvidia, Amazon
- Lululemon downgraded, Dick’s Sporting upgraded: Wall Street’s top analyst calls
- Iqvia upgraded to Buy from Hold at Jefferies
- Stability and Growth Prospects Drive Buy Rating for IQVIA Holdings Amid Leadership Transition